SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Johnson & Johnson Submits Caplyta Application for Bipolar Mania

Johnson & Johnson said it submitted a supplemental new drug application for Caplyta in bipolar mania.

JNJ

Related stories